Risk of nephrogenic systemic fibrosis

Evaluation of gadolinium chelate contrast agents at four american universities

Rebecca Wertman, Ersan Altun, Diego R Martin, Donald G. Mitchell, John R. Leyendecker, Ryan B. O'Malley, Daniel J. Parsons, Edwin R. Fuller, Richard C. Semelka

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Purpose: To retrospectively determine the benchmark incidence of nephrogenic systemic fibrosis (NSF) related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers. Materials and Methods: Institutional review board approval was obtained for this HIPAA-compliant multi-institutional study; the requirement for informed patient consent was waived. Patients who had a diagnosis of NSF between January 2000 and December 2006 were identified at four tertiary care centers with renal transplant and dialysis services. A standard checklist was used to acquire reliable data from the four centers. The diagnosis of NSF was confirmed histopathologically in all patients. The association of NSF development with gadolinium chelate contrast agent administration in each patient was assessed. The type and cumulative dose of contrast agent administered to each patient with NSF were determined at each center by using the standard checklist. The benchmark incidence of NSF was determined and expressed as the ratio of the number of patients with NSF who had undergone gadolinium chelate-enhanced magnetic resonance (MR) imaging, relative to the total number of patients who underwent gadolinium chelate-enhanced MR imaging at each tertiary care center. Benchmark incidences of NSF were compared among the four centers by using Fisher exact tests. Results: Gadodiamide was used at University of North Carolina at Chapel Hill (center A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C) and Thomas Jefferson University (center D) during the study period. Twenty-three patients at center A, nine patients at center B, three patients at center C, and one patient at center D had NSF and had undergone gadolinium chelate-enhanced MR imaging. The incidence of NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44 224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations. Conclusion: The benchmark incidence of NSF was much greater at the two centers where gadodiamide was used than at the two centers where gadopentetate dimeglumine was used.

Original languageEnglish (US)
Pages (from-to)799-806
Number of pages8
JournalRadiology
Volume248
Issue number3
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Nephrogenic Fibrosing Dermopathy
Gadolinium
Contrast Media
gadodiamide
Benchmarking
Gadolinium DTPA
Tertiary Care Centers
Incidence
Magnetic Resonance Imaging
Checklist
Magnetic Resonance Spectroscopy
Health Insurance Portability and Accountability Act
Research Ethics Committees
Informed Consent

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Wertman, R., Altun, E., Martin, D. R., Mitchell, D. G., Leyendecker, J. R., O'Malley, R. B., ... Semelka, R. C. (2008). Risk of nephrogenic systemic fibrosis: Evaluation of gadolinium chelate contrast agents at four american universities. Radiology, 248(3), 799-806. https://doi.org/10.1148/radiol.2483072093

Risk of nephrogenic systemic fibrosis : Evaluation of gadolinium chelate contrast agents at four american universities. / Wertman, Rebecca; Altun, Ersan; Martin, Diego R; Mitchell, Donald G.; Leyendecker, John R.; O'Malley, Ryan B.; Parsons, Daniel J.; Fuller, Edwin R.; Semelka, Richard C.

In: Radiology, Vol. 248, No. 3, 09.2008, p. 799-806.

Research output: Contribution to journalArticle

Wertman, R, Altun, E, Martin, DR, Mitchell, DG, Leyendecker, JR, O'Malley, RB, Parsons, DJ, Fuller, ER & Semelka, RC 2008, 'Risk of nephrogenic systemic fibrosis: Evaluation of gadolinium chelate contrast agents at four american universities', Radiology, vol. 248, no. 3, pp. 799-806. https://doi.org/10.1148/radiol.2483072093
Wertman, Rebecca ; Altun, Ersan ; Martin, Diego R ; Mitchell, Donald G. ; Leyendecker, John R. ; O'Malley, Ryan B. ; Parsons, Daniel J. ; Fuller, Edwin R. ; Semelka, Richard C. / Risk of nephrogenic systemic fibrosis : Evaluation of gadolinium chelate contrast agents at four american universities. In: Radiology. 2008 ; Vol. 248, No. 3. pp. 799-806.
@article{51c2144dbe1443cc83f247e0c17d908f,
title = "Risk of nephrogenic systemic fibrosis: Evaluation of gadolinium chelate contrast agents at four american universities",
abstract = "Purpose: To retrospectively determine the benchmark incidence of nephrogenic systemic fibrosis (NSF) related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers. Materials and Methods: Institutional review board approval was obtained for this HIPAA-compliant multi-institutional study; the requirement for informed patient consent was waived. Patients who had a diagnosis of NSF between January 2000 and December 2006 were identified at four tertiary care centers with renal transplant and dialysis services. A standard checklist was used to acquire reliable data from the four centers. The diagnosis of NSF was confirmed histopathologically in all patients. The association of NSF development with gadolinium chelate contrast agent administration in each patient was assessed. The type and cumulative dose of contrast agent administered to each patient with NSF were determined at each center by using the standard checklist. The benchmark incidence of NSF was determined and expressed as the ratio of the number of patients with NSF who had undergone gadolinium chelate-enhanced magnetic resonance (MR) imaging, relative to the total number of patients who underwent gadolinium chelate-enhanced MR imaging at each tertiary care center. Benchmark incidences of NSF were compared among the four centers by using Fisher exact tests. Results: Gadodiamide was used at University of North Carolina at Chapel Hill (center A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C) and Thomas Jefferson University (center D) during the study period. Twenty-three patients at center A, nine patients at center B, three patients at center C, and one patient at center D had NSF and had undergone gadolinium chelate-enhanced MR imaging. The incidence of NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44 224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations. Conclusion: The benchmark incidence of NSF was much greater at the two centers where gadodiamide was used than at the two centers where gadopentetate dimeglumine was used.",
author = "Rebecca Wertman and Ersan Altun and Martin, {Diego R} and Mitchell, {Donald G.} and Leyendecker, {John R.} and O'Malley, {Ryan B.} and Parsons, {Daniel J.} and Fuller, {Edwin R.} and Semelka, {Richard C.}",
year = "2008",
month = "9",
doi = "10.1148/radiol.2483072093",
language = "English (US)",
volume = "248",
pages = "799--806",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Risk of nephrogenic systemic fibrosis

T2 - Evaluation of gadolinium chelate contrast agents at four american universities

AU - Wertman, Rebecca

AU - Altun, Ersan

AU - Martin, Diego R

AU - Mitchell, Donald G.

AU - Leyendecker, John R.

AU - O'Malley, Ryan B.

AU - Parsons, Daniel J.

AU - Fuller, Edwin R.

AU - Semelka, Richard C.

PY - 2008/9

Y1 - 2008/9

N2 - Purpose: To retrospectively determine the benchmark incidence of nephrogenic systemic fibrosis (NSF) related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers. Materials and Methods: Institutional review board approval was obtained for this HIPAA-compliant multi-institutional study; the requirement for informed patient consent was waived. Patients who had a diagnosis of NSF between January 2000 and December 2006 were identified at four tertiary care centers with renal transplant and dialysis services. A standard checklist was used to acquire reliable data from the four centers. The diagnosis of NSF was confirmed histopathologically in all patients. The association of NSF development with gadolinium chelate contrast agent administration in each patient was assessed. The type and cumulative dose of contrast agent administered to each patient with NSF were determined at each center by using the standard checklist. The benchmark incidence of NSF was determined and expressed as the ratio of the number of patients with NSF who had undergone gadolinium chelate-enhanced magnetic resonance (MR) imaging, relative to the total number of patients who underwent gadolinium chelate-enhanced MR imaging at each tertiary care center. Benchmark incidences of NSF were compared among the four centers by using Fisher exact tests. Results: Gadodiamide was used at University of North Carolina at Chapel Hill (center A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C) and Thomas Jefferson University (center D) during the study period. Twenty-three patients at center A, nine patients at center B, three patients at center C, and one patient at center D had NSF and had undergone gadolinium chelate-enhanced MR imaging. The incidence of NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44 224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations. Conclusion: The benchmark incidence of NSF was much greater at the two centers where gadodiamide was used than at the two centers where gadopentetate dimeglumine was used.

AB - Purpose: To retrospectively determine the benchmark incidence of nephrogenic systemic fibrosis (NSF) related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers. Materials and Methods: Institutional review board approval was obtained for this HIPAA-compliant multi-institutional study; the requirement for informed patient consent was waived. Patients who had a diagnosis of NSF between January 2000 and December 2006 were identified at four tertiary care centers with renal transplant and dialysis services. A standard checklist was used to acquire reliable data from the four centers. The diagnosis of NSF was confirmed histopathologically in all patients. The association of NSF development with gadolinium chelate contrast agent administration in each patient was assessed. The type and cumulative dose of contrast agent administered to each patient with NSF were determined at each center by using the standard checklist. The benchmark incidence of NSF was determined and expressed as the ratio of the number of patients with NSF who had undergone gadolinium chelate-enhanced magnetic resonance (MR) imaging, relative to the total number of patients who underwent gadolinium chelate-enhanced MR imaging at each tertiary care center. Benchmark incidences of NSF were compared among the four centers by using Fisher exact tests. Results: Gadodiamide was used at University of North Carolina at Chapel Hill (center A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest University (center C) and Thomas Jefferson University (center D) during the study period. Twenty-three patients at center A, nine patients at center B, three patients at center C, and one patient at center D had NSF and had undergone gadolinium chelate-enhanced MR imaging. The incidence of NSF was one in 2913 patients who underwent gadodiamide-enhanced MR examinations and one in 44 224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations. Conclusion: The benchmark incidence of NSF was much greater at the two centers where gadodiamide was used than at the two centers where gadopentetate dimeglumine was used.

UR - http://www.scopus.com/inward/record.url?scp=51549119792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549119792&partnerID=8YFLogxK

U2 - 10.1148/radiol.2483072093

DO - 10.1148/radiol.2483072093

M3 - Article

VL - 248

SP - 799

EP - 806

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -